首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.
【24h】

Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.

机译:澳大利亚腹膜透析患者的腹​​膜炎的微生物学和结局。

获取原文
获取原文并翻译 | 示例
           

摘要

We analyzed data from the Australia and New Zealand Dialysis and Transplant Registry for 1 October 2003 to 31 December 2008 with the aim of describing the nature of peritonitis, therapies, and outcomes in patients on peritoneal dialysis (PD) in Australia. At least 1 episode of PD was observed in 6639 patients. The overall peritonitis rate was 0.60 episodes per patient-year (95% confidence interval: 0.59 to 0.62 episodes), with 6229 peritonitis episodes occurring in 3136 patients. Of those episodes, 13% were culture-negative, and 11% were polymicrobial. Gram-positive organisms were isolated in 53.4% of single-organism peritonitis episodes, and gram-negative organisms, in 23.6%. Mycobacterial and fungal peritonitis episodes were rare. Initial antibiotic therapy for most peritonitis episodes used 2 agents (most commonly vancomycin and an aminoglycoside); in 77.2% of episodes, therapy was subsequently changed to a single agent. Tenckhoff catheter removal was required in 20.4% of cases at a median of 6 days, and catheter removal was more common in fungal, mycobacterial, and anaerobic infections, with a median time to removal of 4 - 5 days. Peritonitis was the cause of death in 2.6% of patients. Transfer to hemodialysis and hospitalization were frequent outcomes of peritonitis. There was no relationship between center size and peritonitis rate. The peritonitis rate in Australia between 2003 and 2008 was higher than that reported in many other countries, with a particularly higher rate of gram-negative peritonitis.
机译:我们分析了澳大利亚和新西兰透析与移植注册中心2003年10月1日至2008年12月31日的数据,旨在描述澳大利亚腹膜透析(PD)患者腹膜炎的性质,治疗方法和结局。在6639名患者中观察到至少1次PD发作。总体腹膜炎发生率是每患者年0.60次发作(95%置信区间:0.59至0.62次发作),其中3136例患者发生6229例腹膜炎发作。在这些发作中,有13%为培养阴性,而11%为多菌种。在单一生物腹膜炎发作中,革兰氏阳性菌占53.4%,革兰氏阴性菌占23.6%。分枝杆菌和真菌性腹膜炎发作很少见。对于大多数腹膜炎发作,最初的抗生素治疗使用了2种药物(最常见的是万古霉素和一种氨基糖苷)。在77.2%的发作中,治疗随后改为单一药物。在20.4%的病例中,平均需要6天,需要Tenckhoff导管移除,在真菌,分枝杆菌和厌氧感染中,导管移除更常见,平均移除时间为4-5天。腹膜炎是2.6%患者的死亡原因。转移至血液透析和住院是腹膜炎的常见结局。中心大小与腹膜炎发生率之间没有关系。 2003年至2008年间,澳大利亚的腹膜炎发病率高于其他许多国家,其中革兰氏阴性腹膜炎的发病率尤其高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号